Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07438782 · ClinicalTrials.gov registry record · Phase 1
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT07438782 is a Phase 1 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 97 participants.
The verdict
NCT07438782, a Phase 1 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of testing. The study will also check whether the drug can shrink tumours or slow cancer growth, monitor how the body absorbs and breaks down the drug, and look for any immune reactions that the body might develop against the treatment.
Interventions
- DRUG GSK5533524
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2029-02-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07438782
The ClinicalTrials.gov registry entry for NCT07438782 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK5533524 is the first listed.
NCT07438782 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07438782 about?
NCT07438782 is a clinical study titled "First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors". The purpose of this study is to investigate a new drug GSK5533524 in adults with certain advanced cancers to find a safe dose and learn how well people tolerate it, so researchers can choose the best dose for the next stage of testing. The study will also check whether the drug can shrink tumours or...
What is the current status of trial NCT07438782?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2026-03-23. Estimated completion is 2029-02-06.
What interventions are being tested in trial NCT07438782?
The interventions under investigation include: GSK5533524 (DRUG).
Who is sponsoring clinical trial NCT07438782?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.